Missouri 2026 Regular Session Status: In Committee

SB 1767 — Modifies provisions relating to alternative therapies and treatments, including psilocybin

Last action — Second Read and Referred S Emerging Issues and Professional Registration Committee

  1. ✓
    Introduced
  2. 2
    In Committee
  3. 3
    Passed Senate
  4. 4
    Passed House
  5. 5
    To Executive
  6. 6
    Enacted

This bill is in committee in the Senate. Introduced February 26, 2026. It must pass committee before a floor vote.

Next likely step: a committee vote, then a floor vote in the Senate.

Odds of enactment

Low chance

Based on the sponsor, cosponsors, and committee posture, this bill has a low chance of becoming law.

Upgrade to see the exact probability and what's driving it.

A statistical estimate from our own model of past outcomes — an insight, not a guarantee. Policymaking is volatile.

Prognosis

Stalled 14% · moderate confidence

  • In Committee

    Current position in the legislative process.

  • 1 sponsor

    1 primary, 0 co-sponsors signed on.

Based on stage, sponsorship breadth, committee status, recorded votes, and cross-state momentum — a description of the observable signals, not a prediction.

Summary

SB 1767 - Under this act, any person who acquires, uses, produces, possesses, transfers, or administers psilocybin for the person's own therapeutic use shall not be subject to state or local criminal or civil penalties if the person is a veteran or first responder and is 21 years of age or older and suffers from a condition listed in the act. The person shall be enrolled in a study regarding the use of psilocybin to treat such conditions and shall provide the Department of Mental Health with specified information. A facilitator shall be present during the administration of the psilocybin and the use of psilocybin shall be limited to no more than 150 milligrams of psilocybin analyte during any 12-month period. A person who assists another in any of the acts permitted under this act and any laboratory testing psilocybin under this act shall not be subject to state or local criminal or civil penalties. Subject to appropriation, the Department shall provide grants totaling $2 million dollars for research on the use and efficacy of psilocybin for the treatment of conditions listed in the act. The Department shall prepare annual reports for the Governor, Lieutenant Governor, and the General Assembly on the implementation and outcomes of psilocybin use under this act. No state agency shall disclose to the federal government or any unauthorized third party the statewide list or any individual information of persons who meet the requirements of this act. Additionally, this act modifies current law on the use of investigational drugs and devices for individuals with terminal illnesses to include individuals with life-threatening or severely debilitating conditions or illnesses. Currently, investigational drugs shall not include Schedule I controlled substances. This act repeals that prohibition. This provision is substantially similar to SB 1454 (2026). Finally, this act requires the Department of Mental Health, in collaboration with a Missouri university hospital or contract research organizations conducting FDA-approved trials, to conduct a study on the efficacy of using alternative medicine and therapies, including, but not limited to, the use of psilocybin, for the treatment of veterans and first responders suffering post-traumatic stress disorder, major depressive disorder, substance use disorders, or who require end-of-life care, as described in the act. Such study shall include a study of the use of psilocybin to treat such conditions, as well as a literature review and the submission of various reports. No person participating in the study shall be subject to criminal or civil liability or sanction for participating, except in cases of gross negligence or willful misconduct. This act is identical to SB 1682 (2026), substantially similar to SCS/HCS/HBs 1717 & 1643 (2026) and provisions in SCS/HS/HCS/HBs 3068 & 3049 (2026), and similar to SCS/SB 90 (2025), SCS/SB 768 (2024), HCS/HB 1830 (2024), HB 1154 (2023), and SB 614 (2023). SARAH HASKINS

Bill Text

Action History

  1. Second Read and Referred S Emerging Issues and Professional Registration Committee

  2. S First Read

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 0 co-sponsors · 198 not signed on

Sponsors (1)

Co-sponsors (0)

None.

Not signed on (198)

198 members have not signed on to this bill.

Show all 198 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

public-safety veterans healthcare labor health-insurance technology
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

What does SB 1767 do?
SB 1767 - Under this act, any person who acquires, uses, produces, possesses, transfers, or administers psilocybin for the person's own therapeutic use shall not be subject to state or local criminal or civil penalties if the person is a veteran or first responder and is 21 years of age or older and suffers from a condition listed in the act. The person shall be enrolled in a study regarding the use of psilocybin to treat such conditions and shall provide the Department of Mental Health with specified information. A facilitator shall be present during the administration of the psilocybin and the use of psilocybin shall be limited to no more than 150 milligrams of psilocybin analyte during any 12-month period. A person who assists another in any of the acts permitted under this act and any laboratory testing psilocybin under this act shall not be subject to state or local criminal or civil penalties. Subject to appropriation, the Department shall provide grants totaling $2 million dollars for research on the use and efficacy of psilocybin for the treatment of conditions listed in the act. The Department shall prepare annual reports for the Governor, Lieutenant Governor, and the General Assembly on the implementation and outcomes of psilocybin use under this act. No state agency shall disclose to the federal government or any unauthorized third party the statewide list or any individual information of persons who meet the requirements of this act. Additionally, this act modifies current law on the use of investigational drugs and devices for individuals with terminal illnesses to include individuals with life-threatening or severely debilitating conditions or illnesses. Currently, investigational drugs shall not include Schedule I controlled substances. This act repeals that prohibition. This provision is substantially similar to SB 1454 (2026). Finally, this act requires the Department of Mental Health, in collaboration with a Missouri university hospital or contract research organizations conducting FDA-approved trials, to conduct a study on the efficacy of using alternative medicine and therapies, including, but not limited to, the use of psilocybin, for the treatment of veterans and first responders suffering post-traumatic stress disorder, major depressive disorder, substance use disorders, or who require end-of-life care, as described in the act. Such study shall include a study of the use of psilocybin to treat such conditions, as well as a literature review and the submission of various reports. No person participating in the study shall be subject to criminal or civil liability or sanction for participating, except in cases of gross negligence or willful misconduct. This act is identical to SB 1682 (2026), substantially similar to SCS/HCS/HBs 1717 & 1643 (2026) and provisions in SCS/HS/HCS/HBs 3068 & 3049 (2026), and similar to SCS/SB 90 (2025), SCS/SB 768 (2024), HCS/HB 1830 (2024), HB 1154 (2023), and SB 614 (2023). SARAH HASKINS
Who sponsors SB 1767?
SB 1767 is sponsored by Rick Brattin.
What is the current status of SB 1767?
This bill is in committee in the Senate. Introduced February 26, 2026. It must pass committee before a floor vote.
Where can I track SB 1767?
Track SB 1767 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on SB 1767

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of SB 1767

Last checked for changes about 2 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →